P95 BV (Ampersand-backed) Merges South Africa CRO OnQ Research into P95
October 16, 2023
P95 BV, a vaccine-focused CRO and portfolio company of Ampersand Capital Partners, has signed an agreement to merge South Africa-based contract research organization OnQ Research into P95. The deal, structured as an add-on to P95, expands P95's presence across Africa and enhances its vaccine and infectious-disease clinical research and real-world evidence capabilities.
- Buyers
- P95 BV, Ampersand Capital Partners
- Targets
- OnQ Research
- Platforms
- P95 BV
- Industry
- Healthcare Services
- Location
- Gauteng, South Africa
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
P95 Acquires 4Clinics to Expand Global CRO Services
July 1, 2024
Healthcare Services
P95 BV, an Ampersand Capital Partners portfolio company, has acquired 4Clinics, a contract research organization providing data management, biostatistics, medical writing, regulatory affairs and clinical operations. The acquisition (effective July 1, 2024) integrates 4Clinics' team into the P95 group to strengthen CRO capabilities—particularly in biometrics and medical writing—and to enhance service coverage for Francophone clients.
-
P95 BV Acquires Assign DMB
September 5, 2024
Healthcare Services
P95 BV, a Belgium-based epidemiology and clinical solutions provider backed by Ampersand Capital Partners, has acquired Assign DMB, an Innsbruck, Austria-based clinical research organisation specializing in clinical data management and biostatistics. The deal expands P95's capabilities and capacity to run clinical and non-interventional studies—particularly in vaccines and infectious diseases—and broadens its presence in Europe and globally.
-
Julius Clinical (Ampersand-backed) Merges with Peachtree BioResearch Solutions
May 14, 2025
Healthcare Services
Julius Clinical, a Netherlands-based CRO supported by Ampersand Capital Partners, has merged with Peachtree BioResearch Solutions, a specialized CNS CRO based in Georgia, USA. The merger creates a larger, fully integrated global CRO with expanded CNS capabilities and enhanced access across Europe and North America.
-
RQM+ Acquires Germany-Based CRO Kottmann
August 28, 2023
Healthcare Services
RQM+, a global MedTech services and CRO provider, has acquired CRO Dr. med. Kottmann, a Germany-based contract research organization specializing in clinical studies for medical devices, IVDs and pharmaceuticals. The acquisition expands RQM+'s presence and capabilities in Germany and across Europe, strengthening end-to-end clinical support for its clients.
-
Ampersand Capital Partners Invests in iuvo BioScience
September 28, 2022
Healthcare Services
Ampersand Capital Partners has agreed to acquire a stake in iuvo BioScience, a Rochester-based specialty CRO that provides laboratory, preclinical, clinical development, and scientific consulting services. The investment will fund expansion of iuvo's integrated service portfolio and laboratory capacity and support an active inorganic (add-on) growth strategy; founders Ben Burton and Mary Richardson will remain in leadership roles and as shareholders.
-
Ampersand Capital Partners Majority Recapitalizes Julius Clinical Research
November 28, 2023
Healthcare Services
Ampersand Capital Partners has completed a majority recapitalization of Julius Clinical Research, a Zeist-based clinical CRO, to support geographic expansion and deepen the company's scientific and therapeutic expertise. The investment will help Julius grow its CRO services in CNS, renal, cardiometabolic and infectious disease areas and expand its footprint in Europe and North America.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.